ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Janssen launches PhII/III programme testing Tremfya in Crohn’s
July 12, 2018Janssen has kicked off a Phase II/III programme assessing Tremfya in Crohn's Disease. -
Janssen's Tremfya gets go-ahead from NICE in plaque psoriasis
May 15, 2018NICE, the UK’s drug watchdog for the NHS, has decided that Janssen’s Tremfya (guselkumab) should be used routinely through the health service in the treatment of plaque psoriasis, having judged it an efficient use of financial resources. -
Janssen’s Tremfya backed for NHS use
May 15, 2018Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis. -
New Data Shows TREMFYA Improved Psoriatic Arthritis Symptoms through One Year
November 08, 2017Janssen announced longer-term results from a Phase 2 study investigating TREMFYA (guselkumab), the first selective anti-interleukin (IL)-23 monoclonal antibody to show positive results in the treatment of active psoriatic arthritis.
Pharma Sources Insight January 2025
